Anika Therapeutics
Open
$12.44
Prev. Close
$12.35
High
$12.48
Low
$12.42
Market Snapshot
$178.68M
-16.4
-3.84
$119.91M
235
Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. The company is headquartered in Bedford, Massachusetts and currently employs 235 full-time employees. The firm is leveraging its core expertise in hyaluronic acid and implant solutions. The company partners with clinicians to provide minimally invasive products that restore active living for people around the world. The company is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. The company is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
Anika Therapeutics reported a successful Q4 2025, achieving $30.6 million in revenue and $0.13 EPS, marking a turnaround from prior financial losses.
Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. The company is headquartered in Bedford, Massachusetts and currently employs 235 full-time employees. The firm is leveraging its core expertise in hyaluronic acid and implant solutions. The company partners with clinicians to provide minimally invasive products that restore active living for people around the world. The company is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. The company is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
Recently from Cashu
Anika Therapeutics Reports Strong Q4 Earnings with Focus on Orthopedic Innovation and Growth
Anika Therapeutics Sees Significant Growth in Q4 Earnings: A Focus on Orthopedic Innovation Anika Therapeutics, a leader in the biotechnology sector, releases its Q4 earnings report for the fiscal yea…
Anika Therapeutics Achieves 15% Revenue Growth and Strong Q4 Earnings Amid Strategic Innovations
### Anika Therapeutics Reports Impressive Q4 Earnings Amid Continued Growth Anika Therapeutics (NASDAQ: ANIK) showcases a robust financial performance in its Q4 earnings report released on February 26…
Anika Therapeutics: Leading Innovation in Joint Health and Regenerative Medicine Solutions
Anika Therapeutics: Pioneering Innovations in Joint Health Solutions Anika Therapeutics continues to establish itself as a leader in the regenerative medicine sector, particularly focusing on joint he…
Anika Therapeutics: Leading Innovations in Regenerative Medicine and Patient Care Solutions
### Anika Therapeutics: Pioneering Innovations in Regenerative Medicine Anika Therapeutics continues to position itself at the forefront of regenerative medicine with its groundbreaking developments i…